Healthcare: Who Had the Better Quarter, Gilead Sciences or Amgen?
Podcast |
Industry Focus
Publisher |
The Motley Fool
Media Type |
audio
Categories Via RSS |
Business
Business News
News
Publication Date |
May 15, 2019
Episode Duration |
00:24:32

It's a battle of the big bio's on this episode of Industry Focus Healthcare. Is Gilead Sciences finally overcoming its hep C headwind? Is Amgen beating back biosimilars? We dig into the details as we discuss which of these biopharma behemoths delivered better first quarter results. Stocks: GILD, AMGN

Check out more of our content here:

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review